Study of Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With Schizophrenia - Trial NCT06374290
Access comprehensive clinical trial information for NCT06374290 through Pure Global AI's free database. This Phase 1 trial is sponsored by The University of Texas Health Science Center, Houston and is currently Recruiting. The study focuses on Smoking Cessation. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
The University of Texas Health Science Center, Houston
Timeline & Enrollment
Phase 1
May 01, 2024
Apr 15, 2025
Primary Outcome
Feasibility as assessed by the percentage of participants that enroll in the study,Percentage of participants that complete 3 weeks of treatment,Safety as assessed by the percentage of participants that show no serious adverse events
Summary
The purpose of this study is to assess the feasibility and safety of injectable naltrexone
 (NTX;380 mg) in conjunction with oral bupropion (BUP; 450 mg daily)NTX-BUP administration
 among individuals with schizophrenia spectrum disorders that smoke cigarettes and to evaluate
 change on smoking-related measures and symptoms of schizophrenia.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06374290
Non-Device Trial